Blue Cell Therapeutics

Saxo Bank-milliardæren Lars Seier Christensen har investeret 10 mio. kr. i stamcelleselskabet Blue Cell Therapeutics, der har Søren P. Sheikh som adm. direktør og André Rogaczewski som medejer og storinvestor.

Exciting Times at the LSX Nordic Congress! 🌟 We are thrilled to announce that our colleagues Søren P. Sheikh and Thomas Sandal, represented Blue Cell Therapeutics at the 6th LSX Nordic Congress in Copenhagen! This premier event connects leaders in the life sciences and healthcare sectors with international investors and strategic partners. The congress was a fantastic opportunity for networking and collaboration, fostering connections that will drive innovation and growth in the Nordic life science landscape. We are grateful for the insights shared and look forward to the exciting partnerships that will emerge from this event. Thank you to all who participated and contributed to making this congress a success! #LSXNordic #BlueCellTherapeutics #LifeSciences #Networking

📅 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝐢𝐬 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐬 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐜𝐨𝐦𝐦𝐨𝐧 𝐭𝐲𝐩𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 (other than non-melanoma skin cancer) diagnosed in men . Furthermore, 𝐢𝐭’𝐬 𝐭𝐡𝐞 𝐬𝐞𝐜𝐨𝐧𝐝 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐜𝐚𝐮𝐬𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐞𝐚𝐭𝐡𝐬 𝐢𝐧 𝐦𝐞𝐧, after lung cancer. To prevent and reduce the risks involved with it, it is important to have a 𝐡𝐞𝐚𝐥𝐭𝐡𝐲 𝐝𝐢𝐞𝐭 🥗 , 𝐫𝐞𝐠𝐮𝐥𝐚𝐫 𝐞𝐱𝐞𝐫𝐜𝐢𝐬𝐞 🏃♂️ 𝐚𝐧𝐝 𝐚𝐯𝐨𝐢𝐝 𝐓𝐨𝐛𝐚𝐜𝐜𝐨 & 𝐀𝐥𝐜𝐨𝐡𝐨𝐥 ⛔ Men should discuss with their healthcare provider about 𝐩𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠𝐬, especially if they have a family history or other risk factors. Early detection through PSA tests and digital rectal exams can lead to more effective treatments. Join us in raising awareness and supporting those affected by prostate cancer. Together, we can make a difference. #BlueCellTherapeutics #ProstateCancerAwareness #CancerPrevention #CellTherapy #HealthcareInnovation #ErectileDysfunction #StemCellTherapy #MedicalInnovation

𝐀𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬 𝐯𝐬. 𝐅𝐮𝐭𝐮𝐫𝐞 🔜 🌟 𝐀𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬 🔬 We’ve revolutionized the isolation and culture of adipose-derived stem cells. Our enhanced conditions produce cells with 𝐬𝐮𝐩𝐞𝐫𝐢𝐨𝐫 𝐚𝐧𝐠𝐢𝐨𝐠𝐞𝐧𝐢𝐜 𝐜𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬, improving treatment outcomes. Through rigorous in vitro, ex vivo, and in vivo assays, we've validated the angiogenic potency of our cultured stem cells, setting a new standard in regenerative medicine. 💉 Our 𝐞𝐱𝐢𝐬𝐭𝐢𝐧𝐠 𝐚𝐮𝐭𝐨𝐥𝐨𝐠𝐨𝐮𝐬 𝐚𝐝𝐢𝐩𝐨𝐬𝐞-𝐝𝐞𝐫𝐢𝐯𝐞𝐝 𝐬𝐭𝐞𝐦 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 requires liposuction and on-site cell isolation, which can be inconvenient and painful for patients. 🚀 𝐅𝐮𝐭𝐮𝐫𝐞 𝐕𝐢𝐬𝐢𝐨𝐧 🌐 We are developing an 𝐚𝐥𝐥𝐨𝐠𝐞𝐧𝐞𝐢𝐜 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐡𝐚𝐭 𝐞𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐞𝐬 𝐭𝐡𝐞 𝐧𝐞𝐞𝐝 𝐟𝐨𝐫 𝐥𝐢𝐩𝐨𝐬𝐮𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐫𝐞𝐝𝐮𝐜𝐞𝐬 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐯𝐚𝐫𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲. This ‘off-the-shelf’ product will be more accessible and convenient for patients. Blue Cells will be produced under Good Manufacturing Practice (GMP) conditions. We’re collaborating with industry and biotech partners to advance this innovation through clinical trials and secure EMA and FDA approvals. 🌎 Our goal is to make Blue Cells 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞, offering a groundbreaking solution for erectile dysfunction with enhanced efficiency and ease. #ErectileDysfunction #StemCellTherapy #MedicalInnovation #RegenerativeMedicine #HealthTech #BlueCellTherapeutics #AdvancedStemCells #FutureOfMedicine

𝐌𝐞𝐞𝐭 𝐎𝐮𝐫 𝐒𝐞𝐧𝐢𝐨𝐫 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭: 𝐁𝐞𝐧𝐣𝐚𝐦𝐢𝐧 𝐂𝐥𝐚𝐚𝐬𝐬 🍀 Benjamin Claass is an integral part of our team at Blue Cell Therapeutics. With a distinguished career spanning several companies in the biomedical industry, Benjamin brings expertise, knowledge, and eagerness to solve every upcoming difficulty to our projects. Over the past decade, Benjamin has been deeply involved in developing cancer diagnostics and supporting cell therapy advancements for both leading pharmaceutical companies and start-ups. Benjamin is passionate about pushing the boundaries of science. He is a strong advocate for collaborative work environments and believes in the power of teamwork to achieve groundbreaking results. In the office, Benjamin is always up for a good conversation, offering the most analytical and logical perspectives, all while sporting a smile and his characteristic humor that never fails to get a good laugh. We are proud to have Benjamin Claass as a senior scientist, contributing not only his expertise but also his positive and inspirational outlook. His eagerness and vision are invaluable to our mission at Blue Cell Therapeutics. #BlueCellTherapeutics #CellTherapy #stemcells #meetourteam

🔎 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐄𝐫𝐞𝐜𝐭𝐢𝐥𝐞 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧: 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐎𝐩𝐭𝐢𝐨𝐧𝐬 🤷♂️ Have you ever wondered which were the current treatments available for ED? 💊 You might have heared about Oral Medications PDE5 inhibitors like 𝐕𝐢𝐚𝐠𝐫𝐚 can enhance blood flow and improve erections for many men. ➡ However, did you know that they may cause headaches, dizziness, or upset stomach ? Other radical options such as Penile Implants are suitable for severe ED, surgical implants (inflatable or semi-rigid). Nevertheless, 𝐬𝐮𝐫𝐠𝐞𝐫𝐲 𝐢𝐧𝐯𝐨𝐥𝐯𝐞𝐬 𝐫𝐢𝐬𝐤𝐬 like infection and requires recovery time. 🏃♂️ Lifestyle Changes are always benefitial, potentially greatly improving ED. Unfortunatly unfortunately, results take time and require commitment, and in most of the cases 𝐭𝐡𝐞𝐲 𝐚𝐫𝐞 𝐧𝐨𝐭 𝐞𝐧𝐨𝐮𝐠𝐡. At Blue Cell Therapeutics, we are pioneering an allogenic treatment designed to address 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐭𝐢𝐦𝐞 ED without the drawbacks of current options. #MensHealth #ErectileDysfunction #Wellness #HealthcareInnovation #EDTreatment #BlueCellTherapeutics

𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐋𝐢𝐧𝐤 𝐁𝐞𝐭𝐰𝐞𝐞𝐧 𝐒𝐦𝐨𝐤𝐢𝐧𝐠 𝐚𝐧𝐝 𝐄𝐫𝐞𝐜𝐭𝐢𝐥𝐞 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧 Cigarette smoking continues to pose significant health risks beyond lung cancer and cardiovascular disease. Emerging evidence underscores its profound impact on erectile function, highlighting a critical yet often overlooked aspect of men's health. The physiological mechanism underlies on nitric oxide (NO), essential for penile vasodilation and smooth muscle relaxation crucial for achieving and maintaining erections. Smoking disrupts the NO pathway through various mechanisms. Components of cigarette smoke impair neuronal and endothelial nitric oxide synthase (NOS) enzymes, crucial for generating NO. This impairment leads to reduced vasodilation and compromised blood flow to the penis, contributing directly to ED. Numerous studies have established a clear association between smoking and ED across diverse populations worldwide. Smokers exhibit significantly higher odds ratios for developing ED compared to non-smokers, with risk levels often dose-dependent on smoking intensity and duration. While the damage caused by smoking to erectile function is profound, there is encouraging evidence that quitting smoking can lead to improvements in erectile quality. Studies suggest that younger men and those without significant comorbidities may experience substantial benefits from smoking cessation. Understanding these links underscores the importance of comprehensive health strategies that include smoking cessation interventions to mitigate the risk of ED and improve overall quality of life. As we continue to advocate for healthier lifestyles, addressing smoking's impact on men's sexual health remains a critical priority. #BlueCellTherapeutics #MenHealth #SmokingCessation #ErectileDysfunction #HealthAwareness

𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐚𝐧𝐝 𝐄𝐫𝐞𝐜𝐭𝐢𝐥𝐞 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧 Prostate cancer is a prevalent disease, affecting one in five American men. While treatments like surgery, radiation, and hormone therapy can be life-saving, they often come with significant side effects, including erectile dysfunction (ED). When Can ED Occur After Prostate Cancer Treatment? Some degree of ED typically occurs immediately following surgery, even with nerve-sparing techniques. Surgery can lead to nerve damage, arterial damage, and tissue fibrosis, which causes venous leakage. Recovery can take up to two years if nerves are spared, though recovery is less likely with non-nerve-sparing procedures. Radiation therapy presents a different timeline, with ED usually developing gradually, starting around six months post-treatment. Radiation therapy might spare the erection nerves but can still cause arterial damage and tissue fibrosis. Modern techniques such as brachytherapy, IMRT, and 3-D conformal radiotherapy can reduce the risk but do not eliminate it. When it comes to hormone therapy, Androgen deprivation therapy (ADT) can lead to smooth muscle dysfunction, tissue fibrosis, and hypoactive sexual desire. ED and reduced sexual desire can begin within two to four weeks due to testosterone suppression. Androgen deprivation therapies like Lupron and Zoladex are effective in lowering testosterone levels, but they can also cause significant sexual dysfunction. A landmark study by Schover et al. highlighted the challenges faced by prostate cancer survivors. The survey of 1,236 men revealed that 36% had ED before treatment, which increased to 85% post-treatment. Only 13% reported having reliable, firm erections spontaneously, and just 8% achieved erections with medical aid. Men reported distress not only from ED but also from loss of sexual desire and difficulty achieving satisfying orgasms. #BlueCellTherapeutics #ProstateCancer #ErectileDysfunction #RegenerativeMedicine #SexualHealth #CancerTreatment

𝐓𝐡𝐞 𝐜𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐨𝐧 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐚𝐧𝐝 𝐄𝐫𝐞𝐜𝐭𝐢𝐥𝐞 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧 💡 Did you know that men with diabetes mellitus are three times more likely to experience erectile dysfunction (ED) than those without diabetes? An article from Boston University School of Medicine highlights that this condition is not just an inconvenience, it significantly impacts the quality of life and overall health. ED is seen in 28% of diabetic men versus 9.6% in non-diabetic men. The incidence of ED in diabetic men rises from 15% at age 30 to 55% at age 60. Poor diabetes control and associated complications like vascular and nerve diseases amplify the risk. Diabetes affects penile functions through several mechanisms including psychological factors, central and peripheral nervous system damage, hormonal imbalances, and blood vessel and smooth muscle dysfunction. Arterial blockages are 40 times more prevalent in diabetic men, causing decreased rigidity and frequency of nighttime erections. Electron microscope studies reveal less smooth muscle, more scar tissue, and fewer endothelial cells in diabetic men. Impaired smooth muscle relaxation leads to difficulty maintaining an erection, known as a venous leak. #Diabetes #ErectileDysfunction #MensHealth #BlueCellTherapeutics #SexualHealth 

𝐌𝐞𝐞𝐭 𝐨𝐮𝐫 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭: 𝐉𝐨𝐧𝐞 ✨ Jone Kvam is our dynamic and innovative scientist at Blue Cell Therapeutics, bringing fresh energy and perspective to our team. With a robust background in biological sciences and in vivo studies, Jone contributes to the establishment of in vivo assays and animal models aimed at advancing treatments for erectile dysfunction.   In the lab, Jone is known for their meticulous attention to detail and collaborative spirit. She lives by the quote “I have never tried that before, so I think I should definitely be able to do that” – Pippi Longstocking.   In the office, Jone is the personification of happiness, always branding a wide smile and ready with a hearty laugh. If Jone doesn’t laugh at a joke, you can be sure it wasn’t funny.   Colleagues appreciate Jone’s enthusiasm and willingness to help, making the lab a comfortable workspace, both scientifically and on a collegial level. Jone’s insightful contributions and positive attitude are invaluable to our ongoing projects and overall success at Blue Cell Therapeutics. #BlueCellTherapeutics #CellTherapy #stemcells #meetourteam